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      Abstract 
The oxidoreductase enzymes that comprise the human liver cytochrome P450 (CYP450) 
system are vital in metabolism, lipid synthesis, and detoxification of the human body. It 
is known that enzymes in this pathway process the majority of pharmaceuticals, thus the 
study of these enzymes proves to be valuable in determining potentially harmful drug 
interactions. The amazon acaí berry has gained popularity in recent years due to its 
reported health benefits and has been deemed by many health organizations as a 
superfood. The purpose of this research was to determine the effects of isolated acaí berry 
extracts on the activity of the CYP 450 enzyme 3A4 and 2D6 to determine if there is a 
possible drug interaction. The results obtained suggest that compounds in certain acaí 
fractionations, specifically 94-C (Diosmetin) inhibit the enzymes’ activity by 
approximately 68%. While further research into the metabolism of acaí berries must be 
conducted, these results imply that eating acaí berries may be harmful while taking 
certain medications due to the inability of CYP 3A4 and 2D6 enzymes to adequately 
metabolize the drug. 
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Inhibition of Human Cytochrome P450-3A4 isoform by Crude Extracts from Acai 
Berry 
    The Liver is one of the most important organs in vertebrates. It is located 
in the upper right quadrant of the abdomen, below the diaphragm. The liver has a 
wide variety of functions such as detoxification of various metabolites, protein 
synthesis, and biochemical secretion. In addition, the liver’s unique role is that it 
is responsible for eliminating foreign compounds (xenobiotics) like drugs and 
toxins from the body by specific types of metabolism that involve using 
cytochrome P450 enzymes, which are a family of isozymes responsible for the 
biotransformation of several drugs (1). The synthetic role of the liver will be 
disregarded and the detoxification role of the liver will be focused on due to the 
importance of this research on the human body and the danger that a natural 
product can produce. 
  It is well known that the inhibition or activation of human liver 
cytochrome P450 enzymes by compounds of natural product origin can result in 
adverse drug interactions(19). By inhibiting one or all of the P450 isoforms, the 
Brazilian Acai berry has gained considerable popularity due to its health benefits. 
It can suppress inflammation in individuals with cancer and arthritis. It improves 
digestion along with sexual performance and general health (12). Acai products 
range from the raw freeze-dried powder, supplement tablets, beverages such as 
juice, wine, smoothies or energy drinks, and even food products such as jelly or 
ice cream (19).  
  Human liver cytochrome P450 consists of six different isozymes that play 
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important roles in drug metabolism. CYP1A2, CYP2C19, CYP2C9, CYP2D6, 
CYP2E1, and CYP3A4 (17, 21). The idea that these isoforms could be affected by 
Acai berry came from a classic example of Grapefruit Juice and the plant 
St.John’s Wart (4). Grapefruit Juice was found to have the furanocoumarins 
compound that is responsible for inhibiting the CYP3A4 in two ways, if 
furanocoumarins inhibits the hepatic CYP3A4, it will affect the medication 
metabolism (10, 13). On the other hand, if it inhibits the enterocyte CYP3A4, the 
medication absorption in the intestine would be affected (5). Likewise, Black 
cohosh extracts was found to have a herbal drug interactions that inhibit the 3A4 
and 2D6 human isoforms (22). Human P4501A2, P4503A4, and P4502C9 
isoforms metabolize anticoagulant drugs such as warfarin and clopidogrel that are 
susceptible to pharmacokinetic-related drug interactions with natural products (8). 
Clopidogrel – if used in wrong dosages- would affect the formation of platelets 
and cause internal bleeding (2). Whereas warfarin interacts with nonsteroidal anti-
inflammatory drugs and causes a serious bleeding complications (7).  
    The amazon acaí berry has gained popularity in recent years due to its 
reported health benefits and has been deemed by many health organizations as a 
superfood. In this research, different extracts from the Brazilian acai berry were 
examined for their potential to inhibit human liver cytochrome P450 enzymes to 
determine the effects of isolated acaí berry extracts on the activity of the CYP 450 
enzymes 3A4 to determine if there was the potential for adverse drug interaction. 
The isoform 3A4 was explored with the goal of identifying potential drug-extract 
interactions or identifying specific P450 interactions with potential health benefits 
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(1, 24). To establish this, the activity of the enzyme was measured using a 
commercial assay kit in the presence and absence various acai fractions.  The 
results obtained suggest that compounds in certain acaí fractionations inhibit the 
activity of the human 3A4 up to 70%. Furthermore, by using an activity-guided 
fractionation approach it was determined that one of the primary compounds in 
acai berries that is responsible for this inhibition is diosmetin, which is a known 
flavonoid inhibitor of CYP 450 enzymes. The 3A4 isoform in particular is 
significance with respect to drug interactions involving anticoagulant 
medications. P4503A4 was affected critically by St. John’s wort (A herbaceous 
plant) (16). This plant is a source of hyperforin, an active ingredient that has a 
strong affinity for the pregnane xenobiotic receptor (PXR), as a PXR ligand, 
hyperforin promotes expression of CYP3A4 enzymes in the small intestine and 
liver. This in turn causes induction of CYP3A4 and can reduce the oral 
bioavailability of many drugs making them less effective (14, 23). Furthermore, 
goldenseal was found to be inhibitory to 3A4. 
  7-Benzyloxy quinoline, 7-benzyloxy-trifluoromethylcoumarin, 
 testosterone are the main substrates that is responsible of inhibiting P4503A4, 
These substrate can bind to different domains at the active site of CYP3A4 and 
that any pair can interact with each other in a manner that is distinct from simple 
competitive inhibition. Researches have shown that BQ and BFC show a larger 
inhibition when interacting with a natural product like the ones discussed earlier. 
This is emphasized by highlighting the investigation and prediction of CYP3A4-
ligand interactions. This research would also give knowledge about enzyme 
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substrate binding properties as it may play a major key to the understanding of 
cytochrome P450 inhibition patterns from herbs and drugs (3, 15). 
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    Materials and Methods  
  Acai berry freeze dried extract was purchased from optimally organic Inc. 
The identity of the dried powder was identified by submitting it for genetic 
analysis, which ultimately showed that it is closely related to the authentic acai 
berry sample.  
 Fractionation of the Acai Powder 
   455g of freeze dried acai powder was extracted in 4L MeOH to generate 
methanol extract. The volume was reduced to 2L by filtering the methanol 
fraction. The solution consisted of 9:1:10 ratio of MeOH:H2O:Hexane in a total 
volume of 4L. Since the aqueous MeOH is immiscible with hexane, 19.3g of 
hexane fraction would generate by defatting the original MeOH. The aqueous 
MeOH fraction was dried and partitioned with 4:1:5 chloroform:MeOH:H2O in a 
total of 4L. Finally, the chloroform layer produced 7.2g chloroform and the 
remaining aqueous solution resulted 6.5g butanol and 16.8g aqueous fractions.  
P4503A4 
  10 mM NADP+ stock solution: 382 mg NADP+ in 50 ml Milli-Q water. 
Store at 4 °C. 100 mM glucose-6-phosphate: 3.4 g in 100 ml Milli-Q water. Store 
at 4 °C. 103 IU/ml yeast glucose-6-phosphate dehydrogenase: 1.0 mg in 1 ml 10 
mM Tris-acetate buffer (pH 7.4), containing 20% glycerol (v/v) and 1.0 mM 
EDTA. Store at 4°C. 4 mM BFC stock solution: 2.56 mg in 2 ml methanol. Stored 
in Teflon-sealed amber glass vial at 4 °C. 1 mM ketoconazole stock solution: 5.31 
mg in 10 ml methanol. Stored in Teflon-sealed glass vial at 4°C. NADPH-
generating system: combine 50 parts 10 mM NADP+, 100 parts 100 mM glucose-
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6-phosphate and 1 part 1 mg/ml yeast glucose 6-phosphate dehydrogenase. 
Prepare fresh daily and store on ice when not in use. Stop buffer: 80% acetonitrile 
and 20% 0.5 M Tris-base (v/v), stored at ambient temperature. P450-BFC 2× mix: 
mix P450 3A4 bicistronic membranes and 4 mM BFC stock solution in 100 mM 
potassium phosphate buffer (pH 7.4) so that the final concentration of P450 is 20 
nM and BFC is 40 μM. Prepare the mix fresh daily and keep on ice. Dispense 60 
μl 100 mM potassium phosphate buffer into the wells (column 2–12) in a 96-well 
microplate using a multichannel pipette. Dispense 118 μl 100 mM potassium 
phosphate and 2 μl of 1 mM ketoconazole into the wells (column 1). Serially 
dilute 60 μl inhibitor solution from the wells in column 1 to the other wells (2-10). 
Discard the extra 60 μl solution in the wells in column 10. Dispense 100 μl P450-
BFC 2× mix in all the wells. Add 75 μl stop buffer to the wells in 
column11.Preincubate the plate at 37 °C for 5 minutes.Add 40 μl NADPH 
generating system into each well to initiate the reaction. Incubate the plate at 37 
°C for 20 minutes. Stop the reaction by adding 75 μl stop buffer to each well 
(except wells in column 11) (6, 18). 
  Methodological summary of the fractionation approach that was used in 
this research can be followed by the following: A luminescent commercial 
enzyme assay (Promega P450-Glo Assay) was performed in the presence of 
various acaí berry extracts. The reaction was started using 0.2 mM NADPH and 
stopped using lucifierin detection reagent. The generated luminescent product was 
quantified using a Tecan M200 Pro Infinite plate reader. The assay conditions and 
preparation of samples were in accordance with the 
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recommended Promega protocol. The percent activity of each experimental 
sample was determined and was used to determine the relative amount of 
inhibition caused by each fraction. An identical assay was preformed using 
various concentrations of Diosmetin (94-C) to obtain a dose response curve. The 
results were obtained and analyzed through Microsoft excel. 
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     Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Freeze Dried Acaí Berry 
fractionation Scheme. Amazon dried 
Acai berry was fractionated into multiple 
series. The 34 series represents the most 
crude extracts. The scheme was followed 
to determine the effective dose response 
of the flavonoids that was found to be 94-
H based on the percent activity of each 
fraction. The higher that activity, the less 
the inhibition, so fractions that showed 
lower activity were further fractionated 
and tested. 
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Table 1. % Activity 3A4-34 Series fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
Fraction           Luminescence         Percent of + 
Positive 7746.5 100 
34-7 1086.667 14 
34-8 768 10 
34-9 1973.5 25 
   
Positive 3378.25 100 
34-1 618 18 
34-2 1083 32 
34-6 984.125 29 
34-10 558.125 17    
Positive 5729.5         100 
      34-3 1339 23 
      34-4 2532.25 44 
       34-5 1545.25 27 
Figure 2. 34 Series inhibition of 
CYP 3A4. The percent activity of 
each sample was determined by 
comparing the luminescent values of 
each experimental sample to the 
luminescence of the positive control. 
The fractions were added at a 
concentration of 25 mg/mL. While 
many fraction showed strong 
inhibition, 34-8 proved to be the 
strongest inhibitor with a percent 
activity of 10%. 
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  Table 2. % Activity 3A4-38 Series fractions 
  
Fraction                             Percent of +  
Positive 100 
38-1 37 
38-2 27 
38-3 30 
38-4 26 
38-5 28 
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            Table 3. % Activity of 3A4-62 Series. 
Fraction Luminescence Percent of + 
Positive 5346 100 
62-1 3972.75 74 
62-2 2029 38 
Positive 7309 100 
62-3 2501 34 
62-5 2447.5 33 
Figure 3. 38 Series inhibition of CYP3A4. The final concentration of 
fraction in each sample was 25 mg/mL. While all fractions evidenced a 
similar level of inhibition, all with a percent activity 30-40%, it was 
determined that subsequent fractionations from 38-3 would be tested due to 
their relative availability.  
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Table 4. % Activity of 3A4-63 series  
Fraction Luminesence Percent of + 
Positive  21704 100 
4 6966 32 
5 8479.5 39 
6 6186 29 
 
 
Figure 4. Percent inhibition of 
3A4-62 series. The activity of the 
fractions of the 62 series was 
compared with a positive control. 
The lumenescence activity of 
50uL/mg of each fraction were 
used in order to determine the 
inhibition percentage of each 
fraction. Results shows that 62-1 
had the highest inhibition of ~80% 
while 62-2, 62-3, and 62-4 had the 
same inhibition of ~ 8% 
 
CYP450-3A4 INHIBITION  16 
             
 
 
 
  
            Table 5. % Activity of 3A4-98 Series. 
Fraction Luminescence  percent of + 
Positive 821 100 
A 659 80 
B 524 64 
Positive 3705.5 100 
C 1429 39 
D 1253 34 
E 1308 35 
Positive 1759 100 
H 448 27 
I 776 44 
   
 
Figure 5. 63 Series inhibition of 
CYP3A4. The luminescence assays 
preformed with the 63 series had a 
reduced fraction concentration of 5 
mg/mL, due to the increased purity 
of these samples. It was determined 
that fractionations from 63-4 would 
be further analyzed due to its 
significant level of inhibition, 
evidenced by its 38% activity. 
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            Table 6. % activity of four different dilutions of diosmetin. 
Dilutions  precent of + 
Positive 100 
25 23.75596616 
1 63.71390766 
0.5 62.26312556 
0.2 71.72156325 
Figure 6. 94 Series inhibition of 
CYP3A4. The assays carried out 
using the 94 series had a final 
fraction concentration of 5 mg/ml. 
The fractions that provided the 
strongest inhibition were 94-C 
(Diosmetin), 39% activity and 94-
H which provided 27% activity.  
  
CYP450-3A4 INHIBITION  18 
           
 
           
 
 
 
 
Figure 7. Percent inhibition of 
four different dilutions of 
diosmetin. A) The luminescent 
assay previously performed with 
various fractions of acaí berry was 
repeated using various 
concentrations (0.2mM-25mM) of 
purified diosmetin. Bar graph 
shows an increase enzyme 
inhibition when decreasing 
concentration. B) The results 
suggest that the effective inhibitory 
dose of diosmetin is between 1-
A 
B 
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  The results of this experiment strongly suggest that compounds in acaí 
berries inhibit CYP 3A4 in vitro. The results from the most crude chloroform 
extracts tested, 34 series, suggest that the majority of these fractions significantly 
inhibit CYP3A4 (Figure 1). These results were obtained by comparing the 
luminescence activity of each fraction to the value of the positive control. 
Reactions were carried in a 25µg/ml molar concentration. Concentrations were 
determined based on the purity of the sample factions which differ depending on 
the fractionation method and the place where they have originated from. Most 
notably, 34-8 proved to be the strongest inhibitor of CYP3A4, which is evidenced 
by 3A4’s low percent activity of 10% in the presence of this fraction. A low 
percent activity means that there is large percent inhibition of the enzyme in the 
fraction. 
  Upon continuation of the activity guided fractionation approach, it was 
discovered that fractions in the 38 series all inhibit 3A4 to a similar level (30-40% 
activity); however, fractions from 38-3 were further pursued due to its relative 
availability (Figure 2). Table 2 shows the values of the luminescence activity of 
the 38 series fractions. Percentages are relatively close (26%-37%). 
  The activity guided fractionation approach was further performed on the 
63 series. The assay results from the 63 series indicated that both 63-6 and 63-4 
were inhibitors of CYP 3A4, both yielding a percent activity around 40% (Figure 
3). Reactions were carried on a 5µg/ml plate reader wells. This reduction in 
concentration is due to the purity of the fractions. Due to its significant inhibition, 
fractionations from 63-4, 94 series, were tested. Potency of diosmeting on 
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CYP3A4 was determined using the same fractionation approach, it was 
discovered that 94-C and 94-H were the most potent inhibitors with a percent 
activity of 39% and 27%, respectively.  
  The identity of 94-C was previously determined to be the flavonoid 
compound Diosmetin, also known as 5,7,3'-trihydroxy-4'-methoxyflavone, which 
is a known inhibitor of CYP enzymes (2). Diosmetin is an O-mythelated flavone 
that was found to waken tyrosine kinase enzyme. In addition, it was found to play 
a role pharmacologically by being anti cansourous, antioxidant, anti-
inflammatory, and also, antimicrobial. In order to determine the effective 
inhibitory dose of Diosmetin on 3A4, a dose response curve was produced (Figure 
6) (11). It was determined that the effective inhibitory dose of Diosmetin is 
between 1-5mM, which is evidenced by the large decrease in enzyme activity 
between these two concentrations (Figure 6b). 
  The quantity of acaí berries that must be consumed to reach this inhibitory dose of 
Diosmetin is unknown, as the concentration of this compound in crude acaí berry 
has not yet been determined. It was also found that fractions 34-1 and 94-H 
strongly inhibit 3A4. The identity of these fractions is currently being determined 
by an outside source. 
  The cytochrome p450 family has a liege group of enzyme that is found 
predominantly in the liver. This group of enzymes is responsible for various 
functions, the most primary functions being metabolism of both nutrients and 
exogenic components such as pharmaceuticals. It is known that cytochrome p450-
3A4 is larger responsible for metabolizing pharmaceuticals. It has been 
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approximated that this enzyme is responsible for metabolizing 30% of 
pharmaceuticals that are currently on the market. Further studies have shown that 
this enzyme is inhibited by certain components of grapefruit. Thus, inhibition of 
this enzyme while taking certain drugs, such as statins, has been shown to be 
harmful due to the inability of drug clearance; as a result, toxic levels of drugs 
build up in the system resulting in prolonged defects of these drugs and magnified 
effects of these drugs, both of which lead to undesirable outcome.  
  Similar studies are currently being explored and pursued as acai berry is 
being tested for potential inhibition effects on this enzyme looking for potential 
DDI. While diosmetin was found to be largely responsible for inhibition of 
CYP3A4 in the presence of acai berry fractions, further research must be done to 
further explore how acai berry is actually metabolized in vivo and weather 
diosmetin is conjugated with other proteins or flavonoids in vivo. 
   Results from these further studies can help illustrate how relevant acai 
berry in to inhibiting CYP 3A4 in a physiological settings. Another component of 
further research that must be determined is the amount of diosmetin per gram or 
volume of acai berry as it will prove to be relevant in dosage information 
regarding how much acai has to be consumed to revive an effective dose of 
diosmetin to inhibit CYP 4A4. The goal of this research was to determine if there 
was an adverse drug interaction caused by acai berry on CYP 3A4. These 
preliminary studies suggest that there is such a negative correlation between 
diosmetin and CYP 3A4 potentially leading to verifying that acai berry fractions 
and components of acai berry, specifically diosmetin, may inhibit the enzyme 
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3A4, thus leading to a toxic build-up of certain substrates of 3A4 mainly which 
are pharmaceuticals (9), thus leading to potential toxicity of these drugs while 
consuming acai berry. The relevance of this research might be avoiding 
consumption of acai berry while taking certain drugs such as statins. 
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      Future Research 
  Future research is to be conducted in order to reinforce the finding that diosmetin 
is the primary inhibitor of CYP3A4 found in acaí berries. The dose response that this 
flavonoid can cause in the bod due to a specific amount of acai berries intake is also to be 
determined. Pharmaceutical products consumption along with the acai berries is 
dangerous and can cause drug-drug interactions. Furthermore, 94-H fraction is marked as 
a potential inhibitor of CYP3A4 isoform (20). 
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